MannKind: Inhaled Insulin Can Beat ‘Niche’ Rap
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical benefit will overcome payers’ reluctance, exec tells “The Pink Sheet” DAILY.
You may also be interested in...
NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.
NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.
NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner
Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.